Circulatinglong non-coding RNA FEZF1-AS1 and AFAP1-AS1 serve as potential diagnostic biomarkers for gastric cancer

BackgroundGrowing evidence indicates that two long non-coding RNAs (lncRNAs), FEZ family zinc finger 1 antisense RNA 1 (FEZF1-AS1) and Actin filament associated protein 1 antisenseRNA1 (AFAP1-AS1), are highly expressed in different cancers, including gastric cancer (GC). However, the expression pattern and clinical utility of these two lncRNAs are still unknown.MethodsSerum expression levels of FEZF1-AS1 andAFAP1-AS1 were measured by quantitative real-time polymerase chain reaction (qRT-PCR). CEA and CA19-9 were detected by ARCHITET I2000 SR. Analyses were all performed using SPSS software version 20.0 (SPSS Inc., Chicago, USA). P < 0.05 was considered statistically significant.ResultsDetection of serum FEZF1-AS1 and AFAP1-AS1 showed both of them were up-regulated in GC patients compared with the normal controls (p < 0.0001), and high serum expression levels were correlated with tumor size, tumor-node-metastasis (TNM) stage and lymph node metastasis. Besides, the area under the ROC curve (AUC) demonstrated the two lncRNAs had higher diagnostic utility than CEA and CA19-9. Furthermore, when combined the two lncRNAs as a model, it yielded an AUC of 0.866, and the combination of the model, CEA and CA19-9 could observably improve diagnostic sensitivity to 95.5 %. What’s more, circulating FEZF1-AS1 and AFAP1-AS1 were significantly decreased after the GC patients underwent the operation (both p < 0.001).ConclusionOur study indicated that serum FEZF1-AS1 and AFAP1-AS1 had better sensitivity and efficiency for the diagnosis of GC and the combination of the two lncRNAs might be used as a potential prognostic indicator in GC.     

长链非编码RNA CCAT2在肿瘤中的研究进展

长链非编码RNA(LncRNA)是继微小RNA(miRNA)之后非编码RNA(ncRNA)研究的热点.LncRNA在基因组中普遍转录,由于其在转录调控、转录后调控和表观遗传调控中的不同功能,使其正在成为肿瘤发生研究的新热点.结肠癌-相关转录本2(CCAT2)作为一种长链非编码RNA首先在大肠癌中被发现并命名,后被证实在其他多种肿瘤如乳腺癌、卵巢癌、胃癌、非小细胞肺癌、子宫颈癌、食管鳞状细胞癌的发生发展中存在异常表达,说明C C A T 2可以作为肿瘤标记物广泛应用.     

长链非编码RNA BCYRN1与相关疾病的研究进展

BCYRN1是一种长链非编码RNA,在大脑中高水平表达,并在多种肿瘤类型和其他系统疾病中表达升高。随着对BCYRN1研究的深入,发现BCYRN1与肿瘤、神经系统疾病、呼吸系统疾病以及其他系统疾病密切相关并扮演着重要角色。本文总结了BCYRN1在不同疾病的作用及相关机制的研究进展,为深入了解BCYRN1是如何影响和促进疾病的发生、发展过程提供一点参考或启示。     

敲低长链非编码RNA AFAP1-AS1抑制TPC-1甲状腺乳头状癌细胞上皮间质转化及其侵袭和迁移

目的 检测甲状腺乳头状癌组织长链非编码RNA (lncRNA)肌动蛋白丝相关蛋白1反义RNA1(AFAP1-AS1)的表达,敲低TPC-1甲状腺乳头状癌细胞AFAP1-AS1,研究其对TPC-1细胞上皮间质转化(EMT)的影响及相关分子机制.方法 采用实时定量PCR检测60例甲状腺乳头状癌组织lncRNA AFAP1-...     

TP73-AS1在肿瘤中的表达及调控作用

<正>随着高通量测序技术的发展,成千上万种长链非编码RNA(long non-coding RNA,lncRNA)进入人们的视野。lncRNA是一类长度超过200个核苷酸并缺少开放阅读框的不具备蛋白质编码功能的RNA~([1-2])。研究发现lncRNA参与诸多生物学进程的关键步骤,包括染色质重塑、基因转录、转录后调节和蛋白质翻译等~([3-5])。LncRNA机制的不断被阐明,也为肿瘤的研究提供了新的可能。LncRNA在多种肿瘤的增殖、迁移侵袭和抗凋亡     

长链非编码RNA在 疫应答中的研究进展

随着高通量测序的出现,人类基因组中证实存在一类没有蛋白编码功能、长度大于200个核苷酸的长链非编码RNA (lncRNA),经进一步的深入研究,发现其与肿瘤、心脑血管等疾病的发病密切相关.然而,lncRNA在免疫系统中的作用研究尚属一个新兴领域,近些年来的研究表明lncRNA亦参与了免疫调节的过程,在固有免疫和适应性免疫中发挥着不容忽视的作用.因此,对免疫系统中lncRNA功能的阐述将有助于理解各种免疫性疾病的发病机制.     

长链非编码RNA在肺癌中的研究进展

长链非编码RNA（LncRNA）是一类转录本长度超过200nt的RNA,不编码蛋白,大多数位于细胞核,以RNA的形式在多层面上（表观遗传调控、转录调控以及转录后调控等）调控基因的表达水平。其广泛参与机体的生理和病理过程,在恶性肿瘤的发生和发展中起着重要作用。     

Long non-coding RNA OIP5-AS1 promotes cell proliferation and aerobic glycolysis in gastric cancer through sponging miR-186

IntroductionLong non-coding RNAs (lncRNAs) play vital roles in tumour initiation and progression. LncRNA OIP5-AS1 is a potential oncogene in many types of human malignancies, but its biological functions in gastric cancer (GC) remain to be further elucidated.Material and methodsThe expression levels of OIP5-AS1 and miR-186 in GC tissues and cell lines were detected by RT-qPCR analysis. CCK-8 assay and colony formation assay were performed to investigate the proliferation of GC cells in vitro, and a nude mouse tumour model was established to validate the role of OIP5-AS1 in GC tumorigenesis in vivo. The glucose consumption and lactate production of GC cells were detected by ELISA assay. Interaction between OIP5-AS1 and miR-186 was determined using dual luciferase reporter assay.ResultsThe results demonstrated that OIP5-AS1 was upregulated in GC tissues and cell lines and that its high expression was notably correlated with aggressive clinicopathological features of GC patients. Functionally, knockdown of OIP5-AS1 inhibited GC cell proliferation and enhanced cell apoptosis in vitro, and inhibited GC xenograft growth in vivo. In addition, knockdown of OIP5-AS1 reduced the glucose consumption and lactate production in GC cells. In particular, OIP5-AS1 may function as a ceRNA for miR-186, and inhibition of miR-186 blocks the effects of OIP5-AS1 knockdown on aerobic glycolysis in GC cells.ConclusionsAccordingly, our findings suggested that the OIP5-AS1/miR-186 axis might be considered as a potential therapeutic target for GC patients.     

长链非编码RNA调控细胞凋亡及自噬的研究进展

<正>细胞死亡根据其表观形态学特征分为:凋亡、自噬、坏死等,随着研究的进展,逐步发现了其它多种死亡类型。细胞死亡是胚胎发育、组织稳态和免疫调节的基础。机体通过多种不同的细胞死亡方式维持各种组织、器官的正常运行以及机体内环境的稳态。细胞死亡机制的失调可引起肿瘤等多种疾病。近年来研究显示,长链非编码RNA(long non-coding RNA,lncRNA)在细胞中表达水平上的差异与多种     

长链非编码RNA在结肠癌组织与癌旁组织中的表达研究

目的:筛选出结肠癌差异表达的长链非编码RNA(lncRNA),并分析其在结肠癌组织和相应癌旁组织中的差异表达情况。方法:从lncRNAtor数据库下载结肠癌组织中差异表达的lncRNA数据(Colon adenocarcinoma:Person neoplasm cancer status),包含36例结肠癌组织及29例正常结肠组织,以P0.01且差异表达倍数大于2或小于0.5的条件筛选出lncRNA,并用real-time PCR进一步验证其在60对结肠癌组织及癌旁组织中的表达情况。结果:分析结肠癌lncRNA数据发现,与正常组织相比,结肠癌组织共有50个lncRNA差异表达,其中28个高表达,22个低表达(P0.01)。筛选的4个lncRNA在60对结肠癌及癌旁组织标本中的验证结果为:HNF1AAS1和ZDHHC8P1的表达均上调(P0.01),SUZ12P表达下调(P0.05)。临床Ⅰ-Ⅱ期结肠癌组织中HNF1AAS1的表达水平明显低于Ⅲ-Ⅳ期(P0.05),ROC曲线分析显示,HNF1A-AS1、ZDHHC8P1和SUZ12P诊断结肠癌的ROC曲线下面积(AUC)分别为0.729(敏感性为78%,特异性为67%)、0.617(敏感性为68%,特异性为55%)和0.689(敏感性为65%,特异性为55%)。结论:长链非编码HNF1A-AS1和ZDHHC8P1在结直肠癌组织中表达上调,SUZ12P在结直肠癌组织中表达下调,其表达水平可能与结肠癌的发生存在关联。     

长链非编码RNA与糖尿病关系的研究进展*

Long non-coding RNAs (lncRNAs) are a group of RNAs, which are longer than 200 nucleotides without containing functional open reading frame and cannot encode protein. The study of lncRNA will help to understand the multi-level expression regulatory network of the body, and is expected to provide the basis of prediction, diagnosis and treatment of complex diseases. Although the functions and mechanism of lncRNA remain unclear, some studies indicate that lncRNA is involved in the development of diabetes mellitus, and those lncRNAs may be new diagnostic markers and therapeutic targets.     

长链非编码RNA调控不同来源干细胞成骨分化机制的研究进展

肌腱病是世界范围内的常见疾病,无论手术与否,肌腱钙化均是其最常见的并发症之一.然而,肌腱病导致肌腱钙化的发病机制尚不清楚,有证据表明此病理改变可能与肌腱组织中外源性或内源性的干细胞异常成骨分化有关.近年来,长链非编码RNA(lncRNA)参与调控不同来源干细胞成骨分化成为研究热点,这也为解决相应的临床问题提供了一个新方...     

长链非编码RNA及其在免疫系统中的研究

长链非编码RNA(lncRNA)一直被认为是“暗物质”而未受到人们的重视,直至2007年,斯坦福大学的研究者报道了同源异型基因转录反义RNA (HOTAIR)作为一种lncRNA可与蛋白复合体polycomb相互作用,并抑制同源异型基因(HOX)的转录,参与生物体生长发育的调节过程.自此之后,lncRNA受到了广泛的关注.lncRNA可以在表观遗传学水平、转录水平、转录后水平调节包括基因印迹、细胞定向分化、细胞增殖、细胞周期、肿瘤、神经退行性疾病、免疫细胞的发育与分化以及机体免疫反应的调节等多种病理生理过程.因而研究lncRNA的定义、分类及其发挥功能的机制具有重要意义.     

LncRNA-DANCR: A valuable cancer related long non-coding RNA for human cancers

Objectives

Long noncoding RNAs (lncRNA) are a type of noncoding RNA that comprise of longer than 200 nucleotides sequences. They can regulate chromosome structure, gene expression and play an essential role in the pathophysiology of human diseases, especially in tumorigenesis and progression. Nowadays, they are being targeted as potential biomarkers for various cancer types. And many research studies have proven that lncRNAs might bring a new era to cancer diagnosis and support treatment management. The purpose of this review was to inspect the molecular mechanism and clinical significance of long non-coding RNA- differentiation antagonizing nonprotein coding RNA(DANCR) in various types of human cancers.

Expression of long non-coding RNA LOC285194 and its prognostic significance in human pancreatic ductal adenocarcinoma

Introduction: Dysregulation of long non-coding RNAs (lncRNAs) plays critical roles in tumor progression. lncRNA LOC285194 was previously shown to be correlated with aggressive clinicopathological features and poor prognosis in several cancers. The aim of this study was to investigate relationship between LOC285194 expression and clinical outcomes in human pancreatic ductal adenocarcinoma (PDAC). Methods: Quantitative real-time PCR (qRT-PCR) assay was performed to detect the expression of lncRNA LOC285194 in human PDAC cells and tissue samples. The association of LOC285194 expression with clinicopathologic features was analyzed. Kaplan-Meier analyses were used to assess survival of patients. Univariate and multivariate analyses were performed using the Cox proportional hazards model to analyze the prognostic significance of LOC285194 expression. Results: Our data showed that the relative level of LOC285194 in PDAC cells was significantly lower than that in normal human pancreatic duct epithelial cell line. Also, the expression of LOC285194 in PDAC tissues was significantly lower than that in adjacent non-tumor tissues. By statistical analyses, low LOC285194 expression was observed to be closely correlated with clinical stage, lymphnode metastasis and liver metastasis. Kaplan-Meier survival analysis revealed that patients with low LOC285194 expression had a poor overall survival compared with the high LOC285194 group (P < 0.05). Univariate and multivariate analyses showed that low LOC285194 expression was an independent poor prognostic factor for PDAC patients. Conclusions: Our data provided the first evidence that reduced LOC285194 in PDAC tissues was correlated with tumor progression, and lncRNA LOC285194 might be a potential molecular biomarker for predicting the prognosis of patients.     

Prognostic value of long non-coding RNA FOXD2-AS1 expression in patients with solid tumors

BackgroundAlthough increasing evidence has revealed that FOXD2-AS1 overexpression exists in various solid tumors, the value of FOXD2-AS1 as a prognostic marker in such cancers remains uncertain. Accordingly, the present research aimed to assess the association of FOXD2-AS1 with cancer prognosis and predict the biological function of FOXD2-AS1.MethodsWe systematically retrieved PubMed, PMC, Web of Science, EMBASE and Wiley Online Library databases for eligible articles published up to December 2018. Pooled hazard ratios (HRs) and odds ratios (ORs) with 95% confidence intervals (95%CIs) were calculated to evaluate the correlation of FOXD2-AS1 expression with overall survival (OS), disease free survival (DFS) and clinicopathological characteristics. We also used five Gene Expression Omnibus (GEO) datasets from breast cancer patients to explore the relationship between FOXD2-AS1 expression and prognosis. Finally, we validated FOXD2-AS1 expression in various carcinomas and predicted its biological function based on the public databases.ResultsA total of 13 studies with 2502 tumor patients were included. The pooled HRs demonstrated that FOXD2-AS1 overexpression was significantly associated with unfavorable OS (HR = 1.39, 95%CI: 1.23–1.57, p < 0.001) and DFS (HR = 2.24, 95%CI: 1.55–3.23, p < 0.001) in tumor patients. The pooled ORs indicated that FOXD2-AS1 upregulation was related to large tumor size (OR = 1.53, 95%CI: 1.26–1.85, p < 0.001), deep invasion depth (OR = 1.99, 95%CI: 1.53–2.58, p < 0.001), distant metastasis (OR = 2.03, 95%CI: 1.69–2.43, p < 0.001) and advanced TNM stage (OR = 1.35, 95%CI: 1.06–1.72, p = 0.0150), but not to lymph node metastasis nor differentiation. Moreover, a similar pooled result for the OS of breast cancer patients was obtained (HR = 1.55, 95%CI: 1.14–2.11, p = 0.0052) by analyzing GEO data. Finally, elevated FOXD2-AS1 expression in various solid tumor tissues was verified based on The Cancer Genome Atlas (TCGA) data. Further functional prediction demonstrated that FOXD2-AS1 may participate in some cancer-related pathways.ConclusionElevated FOXD2-AS1 expression was associated with poor survival in patients with solid tumors and may serve as a potential prognostic biomarker for a variety of cancers.     

长链非编码RNA MEG3对肿瘤细胞调控作用的研究进展

长链非编码RNA(long non-coding RNA,lncRNA)是一类长度超过200 nt的不编码蛋白的RNA分子。lncRNA最初被认为是转录噪音,在近年的研究中发现越来越多功能性的lncRNA,其重要性才渐渐被阐述。母系表达基因3(materally expressed gene 3,MEG3)是一种由母系印记基因编码的lncRNA,在对其功能的研究中发现MEG3几乎参与了所有的生理和病理过程,其在多种肿瘤中表现出抑制作用。本文就lnc RNA MEG3对肿瘤细胞调控的作用机制作一综述。     

Expression of long non-coding RNA SFTA1P and its function in non-small cell lung cancer

Non-small cell lung cancer (NSCLC) is a major type of lung cancer with high morbidity and mortality. Long non-coding RNAs (lncRNAs) have been reported to be important in development and progression of NSCLC. However, the role of lncRNA SFTA1P remains unclear. This study aims to explore the clinical roles, biological function, and mechanism of SFTA1P in NSCLC. SFTA1P expression was estimated by the quantitative real-time polymerase chain reaction (qRT-PCR) of 90 pairs of tissue samples, the Cancer Genome Atlas (TCGA) database and microarray. After overexpressing SFTA1P, NSCLC cell proliferation, cycle, and apoptosis were detected. We found that the expression of SFTA1P was significantly downregulated in NSCLC tissues with high diagnostic value (AUC = 0.87), which was consistent with the results of TCGA and microarray data. For the analysis of clinical features, the results revealed that SFTA1P expression was closely related to the pathological type (P < 0.01). Furthermore, the cell function results suggested that the overexpression of SFTA1P triggered cell cycle arrest in the S-phase (P < 0.05). From a mechanistic perspective, the results showed that the PI3K-AKT signaling pathway was inhibited after overexpression of SFTA1P in NSCLC. Taken together, this work supported that SFTA1P may play a suppressing role in the tumorigenesis of NSCLC by modulating PI3K-AKT signaling pathway to influence cell cycle, which provides a potential and prospective biomarker for NSCLC.